A registrational trial of RP-L102 for Fanconi's Anemia
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs RP L102 (Primary)
- Indications Fanconi's anaemia
- Focus Registrational; Therapeutic Use
- 07 Nov 2019 According to a Rocket Pharmaceuticals media release, first patient treatment is anticipated in Q4 2019.
- 04 Sep 2019 According to a Rocket Pharmaceuticals media release, based on feedback from a recent End-of-Phase 1 meeting with the U.S. FDA, the company plans to open enrolment in this trial in Q4 2019. This trial will enrol up to five patients in the U.S.
- 24 May 2018 New trial record